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Abstract 
Background: O6-methylguanine-DNA-methyltransferase (MGMT) promoter 
methylation status is a predictive biomarker in glioblastoma. We investigated whether 
this marker furthermore defines a molecularly distinct tumor subtype with clinically 
different outcome.  
Methods: We analyzed copy number alteration (CNV) and methylation profiles of 
1095 primary and 92 progressive Isocitrate dehydrogenase (IDH) wildtype 
glioblastomas, including paired samples from 49 patients. DNA mutation data from 
182 glioblastoma samples of The Cancer Genome Atlas (TCGA) and RNA 
expression from 107 TCGA and 55 Chinese Glioma Genome Atlas samples were 
analyzed.  
Results: Among untreated glioblastomas, MGMT promoter methylated (mMGMT) 
and unmethylated (uMGMT) tumors did not show different CNV or specific gene 
mutations, but a higher mutation count in mMGMT tumors. We identified three 
methylation clusters. Cluster 1 showed the highest average methylation and was 
enriched for mMGMT tumors. Seventeen genes including GBX2 were found to be 
hypermethylated and downregulated on mRNA level in mMGMT tumors.  
In progressive glioblastomas, PDGFRA and GLI2 amplifications were enriched in 
mMGMT tumors. mMGMT tumors gain PDGFRA amplification whereas uMGMT 
tumors with PDGFRA amplifications frequently lose this amplification upon 
progression. Glioblastoma patients surviving < 6 months and mMGMT harbored less 
frequent EGFR amplifications, more frequent TP53 mutations and a higher TNF-
NFκB pathway activation compared to patients surviving longer than 12 months.  
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Conclusions: MGMT promoter methylation status does not define a molecularly 
distinct glioblastoma subpopulation among untreated tumors. Progressive mMGMT 
glioblastomas and mMGMT tumors of patients with short survival tend to have more 
unfavorable molecular profiles. 
 
Keywords 
O6-methylguanin-DNA methyltransferase (MGMT), glioblastoma biomarker, TERT, 
NFκB, PDGFRA 
 
Importance of the Study 
This study compares more than 1200 glioblastomas from three sources for 
differences in methylation, CNV, mutation and RNA expression according to their 
MGMT promoter methylation status. There was an uneven distribution of MGMT 
promoter methylation in three defined methylation clusters, despite otherwise similar 
molecular profiles. The study is of major relevance for upcoming clinical trials that will 
stratify and include patients with newly diagnosed glioblastoma according to their 
MGMT promoter methylation status and frequently withhold temozolomide in on the 
experimental study arms. Differential analysis of primary and progressive tumors 
revealed differences upon progression including activation of the TNF-NFKB pathway 
and CNV changes in mMGMT tumors that are distinct from uMGMT tumors.  
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Introduction 
O6-methylguanine-DNAmethyltransferase (MGMT) promoter methylation status has 
been consistently identified and used as predictive biomarker for response to 
alkylating chemotherapy in patients with glioblastoma1-3. MGMT is a protein that 
repairs damage induced by alkylating chemotherapies including temozolomide. 
Methylation of the MGMT promoter leads to a reduced MGMT expression4. 
Especially patients with wildtype isocitrate dehydrogenase 1/2 (IDH) genes and an 
unmethylated methylguanine-O6-methytransferase (MGMT) promoter show minimal 
response to chemotherapy with a median survival of just over one year when treated 
with radiochemotherapy after maximal safe resection5.  
The concept of trials with replacement of temozolomide in the experimental arm in 
favor of a combination of an experimental systemic therapy with radiotherapy has 
been successfully established6-9. Preclinical data do not suggest an impact of MGMT 
on radiotherapy, but other treatments have not been systematically evaluated10. 
NOA-04 provided a clinical basis for MGMT promoter methylation status being 
predictive also in IDH wildtype anaplastic gliomas11,12, as did NOA-08 for elderly 
patients with glioblastoma13.   
In the present study, we aimed to evaluate the molecular differences between 
glioblastomas with a methylated or unmethylated MGMT promoter in different 
datasets.  
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Methods 
Glioblastoma patient cohorts 
As of August 2nd, 2016, we screened the Heidelberg 450k methylation array 
database. We identified 1028 glioblastoma samples at diagnosis and 66 glioblastoma 
samples at tumor relapse (see Supplementary Methods) with IDH wild-type. MGMT 
promoter methylation status was determined by the algorithm of Bady et al.14 
Samples were classified as ‘unsure’ and excluded from the analysis if the confidence 
interval of the prediction included the cutoff value of 0.358. Patients provided 
informed consent concerning the use of their tissue samples for research purpose. 
The study was approved by the local ethics committee (No. 206/2005). Of the 1028 
primary tumors, 143 tumors with clinical trial grade clinical follow up data and 
treatment according to the present standard of care were accessible for survival 
analysis.  
 
Illumina 450k array platform analysis 
The Illumina Infinium HumanMethylation450 (450k) array was used to obtain the 
DNA methylation status at 482,421 CpG sites (Illumina, San Diego, CA, USA), at the 
Genomics and Proteomics Core Facility of the German Cancer Research Center 
(DKFZ) (see Supplementary Methods)15.  
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Copy number variation (CNV) analysis 
Copy numbers of single genes were assessed from 450k array data (Details in the 
Supplement).  
The Cancer Genome Atlas (TCGA) data analysis 
TCGA data of 261 glioblastoma specimens at diagnosis were downloaded from the 
cBio portal (www.cbioportal.org)17,18 and from firebrowse (Broad institute, Cambridge, 
MA, firebrose.org)19 on September 12th 2016 (table S1). Only tumor samples with 
IDH 1/2 wildtype and defined MGMT promoter methylation status were used for 
analysis. Clinical data, CNVs, mutation and expression subtype according to the 
classification of Verhaak et al.20 were downloaded from the cBio portal. Methylation 
cluster types of Ceccarelli et al.21 and Sturm et al.22 were obtained from the original 
paper. RNAseq V3 normalized data was downloaded from firebrowse and was 
available for 107 samples meeting the above-mentioned criteria. 450k array 
methylation data was downloaded from the TCGA data portal 
(https://portal.gdc.cancer.gov/) and was available for 67 of the above-mentioned 
tumor samples. 
 
Chinese Glioma Genome Atlas (CGGA) data analysis 
CGGA mRNA microarray data of diffuse gliomas23 including clinical information was 
downloaded from the CGGA website (http://www.cgga.org.cn) on October 25th, 2016. 
Tumors with IDH mutations were excluded. For analysis of short and long surviving 
patients, only samples of patients with survival times < 6 months and > 12 months of 
altogether 55 patients were used (table S1).  
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mRNA data and ingenuity pathway analysis (IPA) 
RNAseq data from TCGA samples were downloaded from firebrose.org as described 
above. We only used samples with available RNAseq data and IDH wild type as well 
as determined MGMT promoter methylation status (n = 107) (Details in the 
Supplement).  
 
Gene set enrichment analysis (GSEA) 
Gene set enrichment analysis was performed with RNAseq data from TCGA samples 
and microarray data from CGGA samples downloaded as described above from 
firebrose.org and cgga.org.cn (see Supplement).  
 
Cluster analysis 
Consensus clustering using k-means was performed with the 10,000 most variable 
methylation positions of the indicated dataset. Clusters were calculated with the R 
extension package ‘ConsensusClusterPlus’24 version 1.38.0. Euclidean distance was 
used for distance measure. The maximum number of evaluated clusters were k = 8.  
 
Statistical analysis and graphics 
Univariate survival analyses were performed using the Kaplan-Meier estimator and 
the log-rank test using the Sigmaplot 12.5 software (Systat Software, Erkrath, 
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Germany). The exact Fisher-Test was used for significance testing for experiments 
with a 2x2 matrix. Values of p < 0.05 were considered significant and asterisked. 
Multiple testing was corrected using the Benjamini-Hochberg procedure. Circos plots 
were generated using the R version 3.3.2 with the extension package ‘OmicCircos‘25. 
Heatmaps and all further graphics were generated using the extension packages 
‘gplots’ and ‘ggplot2’.  
Results 
Differences in the molecular profile of mMGMT and uMGMT tumors at diagnosis 
There were 435/1028 (42%) mMGMT and 593 (58%) uMGMT samples. Patients with 
mMGMT promoter in the Heidelberg cohort had a better outcome (p = 0.001, figure 
1A). In the TCGA cohort, survival analysis of patients who received chemotherapy 
showed a better outcome in the mMGMT tumors subgroup, while no difference in 
patients not receiving chemotherapy (p = 0.008, p = 0.001 and p = 0.94, respectively, 
figures 1A and 1B).  
No significant differences in cyclin dependent kinase 4 (CDK4), mouse double minute 
human homolog (MDM2), cyclin dependent kinase inhibitor 2A (CDKN2A) and 
platelet derived growth factor alpha (PDGFRA) were found when stratifying for 
MGMT promoter methylation status (figure S1A).  
There were no differences between mMGMT and uMGMT tumors in the general DNA 
copy number profile (figure 1C). The percentage of copy number altered genome 
between mMGMT and uMGMT tumors did not differ in the TCGA dataset (figure 1D). 
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In TCGA26, a higher overall number of mutations were reported for mMGMT tumors. 
The absolute number of mutations was higher in mMGMT tumors in in the current 
TCGA cohort (46 vs. 38, p < 0.001, figure 1E). None of the mutation frequencies of 
any single gene differed significantly between mMGMT and uMGMT tumors, but 
there was a trend towards a higher frequency of PTEN mutations in the mMGMT 
group (31.4% vs. 18.5%, p = 0.071). TERT promoter mutations BRAF mutations 
were analyzed in a large dataset by Arita el al.27 After exclusion of IDH mutant and 
lower grade tumors no differences in TERT promoter mutations and BRAF mutation 
frequencies were found according to MGMT promoter methylation (TERT 57.9% vs 
57.8%, BRAF 2.8% vs 2.5%, for mMGMT and uMGMT respectively).  
After excluding CpGs in the proximity to the MGMT gene, we found 2024 positions 
(DMP) with an adjusted p-value ≤ 0.001 and 438 regions (DMR) differentially 
methylated between mMGMT and uMGMT tumors in our 450k array datsets TCGA 
(figure 3A). Filtering by including only CpGs within the promoter region of a gene 
identified 814 differentially methylated positions in 419 different genes (table S2). All 
but three of these positions were hypermethylated in mMGMT tumors. Gene set 
enrichment analysis of differentially methylated positions and regions revealed that 
the top molecular functions of genes in hypermethylated regions in mMGMT tumors 
involve transcription regulation and DNA binding (table S3). Applying a more 
stringent gene selection, we included genes with at least three differentially 
methylated CpGs in one DMR. Ingenuity network analysis of the 87 genes matching 
these criteria found the highest scoring network associated with the functions cell 
death and survival (figure S1B).  
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Gastrulation brain homeobox (GBX) 2, a transcription factor known to stimulate 
proliferation of prostate cancer cells28, was hypermethylated at five CpGs in the 
transcription start site of the methylation dataset (adj. p-values = 3.7 x10-6 – 6.5 x10-7, 
figure S2A) in the mMGMT group and furthermore more than two-fold downregulated 
on RNA level in the mMGMT group in the TCGA dataset, suggesting transcriptional 
repression through promoter methylation in mMGMT tumors (figure 2). Direct 
comparison in 40 samples from TCGA with methylation and RNAseq data revealed 
relevant GBX2 expression only in samples with low methylation of GBX2 and these 
tumors were predominantly uMGMT (figure S2B). In addition to GBX2, 16 genes 
were hypermethylated at a minimum of three CpGs in the combined methylation 
analysis and downregulated in the TCGA RNAseq dataset (figure 2, table S2).  
Consensus clustering using k-means of all samples revealed three different 
subgroups (figure 3A-D). mMGMT tumors were overrepresented in cluster 1 (44% vs. 
31%, p = 0.0001) and underrepresented in cluster 3 (28% vs. 40%, p = 0.0001, figure 
3E). Comparison of tumors from TCGA included in the analyses of Cecarelli et al.21 
and Sturm et al.22 revealed that cluster 1 mainly contains the “LGm4” tumors of 
Cecarelli et al. 21 and the “RTKII classic” tumors of the Sturm et al. classification 22 
(figure 3F). Tumor samples in cluster 1 showed higher mean methylation beta-values 
of differentially methylated CpGs between mMGMT and uMGMT tumors than tumors 
in clusters 2 and 3 (figures 3G), p = 2x10-92 and p = 2x10-186). A hotspot of 
differentially methylated regions on chromosome 6p21-6p22 is described in the 
Supplement. Age at diagnosis was similar between the three clusters (cluster 1: 65.5 
years, cluster 2: 62.7 years, cluster 3: 61.7 years, p values: cluster 1 vs. 2: 0.09, 
cluster 1 vs. 3: 0.05, cluster 2 vs. 3: 0.65). The survival difference between patients 
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with mMGMT and uMGMT tumors were largest in patients with tumors of cluster 1 
(figure S4A, p < 0.001 for cluster 1) and no significant survival difference according to 
MGMT promoter methylation was found for clusters 2 and 3. Chemotherapy was 
given more often in patients of cluster 1, but survival curves were similar when only 
including patients that received chemotherapy (figure S4B). Overall, patients of 
cluster 2 showed worse survival (figure S4C). Of note, Nguyen et al.29 suggested a 
survival benefit of patients with mMGMT only in TERT promoter mutated tumors. As 
TERT promoter mutation increases TERT expression, we analyzed the tumors in the 
different clusters with available RNAseq data. Tumors of cluster 1 showed a 
considerably higher TERT expression levels than tumors of clusters 2 and 3 (figure 
3H, p values: cluster 1 vs. 2: 0.021, cluster 1 vs. 3: 0.010). Conversely, the tumor 
necrosis factor (TNF) - nuclear factor (NF)κB score was highly enriched in tumors of 
cluster 3 (Figure 3I, p values: cluster 1 vs. 3: 0.007, cluster 2 vs. 3: 0.002).   
MGMT showed the lowest p-value for downregulation of all recorded genes in the 
TCGA dataset (p = 3.9 x 10-13, fold change 0.38 for methylated vs. unmethylated). 
Applying p value for difference of p < 0.05 and a fold change of > 2 by RNAseq 
analysis, there were 175 differentially regulated genes.  
 
Analysis of paired tumor samples 
Twenty (48%) of paired tumor samples showed MGMT promoter methylation, 
whereas 29 (52%) did not (figure 4A). Only samples with the same MGMT promoter 
methylation status at diagnosis and progression were included for paired analysis. 
Chemoradiotherapy was received by 42/49 (86%) patients, 3 patients were treated 
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with chemotherapy alone and 4 received radiotherapy alone (table S4). Three of the 
20 (15%) mMGMT tumors acquired PDGFRA amplification or gain at progression, 
whereas none of the uMGMT tumors did. Instead, three progressive uMGMT tumors 
lost their PDGFRA amplification (figures 4A-B). The uMGMT tumor 19 is shown as an 
example for an acquired loss of PDGFRA (figure 4C upper panel) and an acquired 
gain of CDKN2A gene dosage at progression that occurred frequently only in 
uMGMT tumors (21% vs. 0%, p = 0.031, figures 4A-B). Loss of the of CDN2A 
deletion in uMGMT tumor 16 was accompanied by acquired CDK4 amplification upon 
progression (figure 4C middle panel). mMGMT tumor 15 is an example of loss of 
CDKN2A upon progression paralleled by loss of preexisting CDK4 and MDM2 
amplifications (figure 4C lower panel). No major differences were observed in the 
global CNV profiles of paired tumor samples according to MGMT promoter 
methylation status (figures S5A-B). 
 
The frequency of PDGFRA, CDK4 and MDM2 amplification in progressive 
glioblastomas differs according to MGMT promoter methylation 
In 85 samples of progressive glioblastoma (including 66 samples from the Heidelberg 
database, 13 samples from TCGA patients and 6 samples from Wang et al. 16 CNV 
of CDK4, MDM2, PDGFRA and CDKN2A was assessed (figure 5A). Of these tumors, 
32 (38%) were MGMT promoter methylated and 53 (62%) were unmethylated. 
Amplification or gain of the PDGFRA gene was found in 22% of the mMGMT tumors 
and 7.5% of uMGMT samples among progressive tumors (p = 0.092, figure 5B, right 
panel). Furthermore, amplification or gain of CDK4 and MDM2 were found more 
frequently in progressive uMGMT tumors compared to mMGMT tumors (3.1% vs. 
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18.9%, p = 0.046 and 0% vs 13.2%, p = 0.042 respectively, figure 5B, left and middle 
panel). When compared to newly diagnosed glioblastomas, the frequency of CDK4 or 
MDM2 amplifications were significantly lower in mMGMT tumors in the progressive 
setting, but were comparable in uMGMT tumors (figure S6). In progressive tumors 
with 450k array data available, we analyzed a set of 19 frequently altered genes in 
glioblastoma. Besides the differences in CDK4, MDM2 and PDGFRA amplifications 
described above, we found a gain or amplification of the C19MC miRNA cluster and 
the GLI2 gene more often in mMGMT compared to uMGMT tumors (54% vs. 22% 
and 14% vs. 0%, respectively). A higher percentage of MYB deletions was detected 
in uMGMT tumors (36% vs. 9%, figure 5C). The higher rate of C19MC amplifications 
in the mMGMT group was accompanied by a trend towards a higher amplification 
rate of the whole chromosome 19 (figure 5D).  
PCA of progressive tumors in the 450k methylation array dataset did not separate 
tumors according to MGMT status (figure S7A). Applying the same clustering 
algorithm as we did for primary tumors, we identified three different methylation 
groups. mMGMT tumors were overrepresented in cluster 1 (57% vs. 20%, p = 0.005) 
and underrepresented in cluster 3 (10% vs. 43%, p = 0,009, figures S7B-E). 
We found 346 DMPs and 182 DMRs between progressive mMGMT and uMGMT 
tumors (figure S7F). After filtering for positions within the promoter region of a gene 
we identified 196 positions in 152 genes that were differentially regulated between 
both groups. These positions were all hypermethylated in mMGMT tumors. Gene set 
enrichment analysis did not show significantly enriched molecular functions in both 
groups.  
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Twenty-one of the 152 genes (14%) had at least one differentially methylated 
position in the dataset of primary tumors. Of these, within the promoter region of the 
myosin light chain (MYL) 12A, which may be involved in DNA damage repair30, we 
identified five positions that were hypermethylated in progressive mMGMT tumors 
(figure S2C). Three of exactly these five positions were already found to be 
hypermethylated in the dataset of primary tumors.  
 
Comparison of patients with short and long survival revealed differentially regulated 
pathways 
We created groups within the TCGA dataset containing samples of patients who 
survived for either less than 6 months (mMGMT: n = 31, uMGMT: n =34) or more 
than 12 months (mMGMT: n = 43, uMGMT: n = 44) after primary diagnosis. Within 
both the mMGMT and uMGMT groups, patients with a short survival time less 
frequently received alkylating chemotherapy (57% vs. 88% in the methylated group 
and 47% vs. 86% in the unmethylated group) and were older at diagnosis (67.9 vs. 
56.8 years in the methylated and 65.7 vs. 60.0 years in the unmethylated group, 
table S5). Amplification of the EGFR gene was less frequent in tumors with a 
methylated MGMT promoter in patients with death within 6 months after initial 
diagnosis compared to those who lived longer than 12 months or had an 
unmethylated MGMT promoter or both (29% vs. 50%, p = 0.0048, figure 6A). This 
corresponded to a reduced mRNA expression of EGFR in uMGMT patients with short 
survival in two independent datasets of the TCGA cohort derived from RNAseq and 
microarray data.   
Downloaded from https://academic.oup.com/neuro-oncology/article-abstract/doi/10.1093/neuonc/nox160/4093221/Molecular-differences-in-IDH-wildtype-glioblastoma
by guest
on 10 September 2017
Ac
ce
pte
d M
an
us
cri
pt
 
16 
 
TP53 mutations were common in MGMT promoter unmethylated tumors and in 
methylated tumors with a short survival, but were significantly less common in 
mMGMT tumors and a survival time of more than one year compared to the group of 
patients with short survival of less than 6 months (30% vs. 4.5%, p = 0.041, figure 
6B). Like the lower amplification rate of EGFR, there was a trend towards a lower 
EGFR mutation frequency in the mMGMT patients with short survival.  
RNAseq data of tumors of the groups was available for 50 patients. IPA of 
differentially regulated genes on RNA level (figure 6C, table S6) revealed a strong 
prediction of upregulation of TNF-α and the NFκB-complex in tumors from patients 
with short survival with mMGMT compared to patients with longer survival. To 
confirm this finding, we conducted a GSE analysis with a set of genes for signaling of 
TNF-α through NFκB provided by the Broad Institute. This gene set was highly 
enriched in patients with mMGMT tumors and short survival (figure 6C, table S7). 
Conclusively, cellular movement and proliferation were enhanced in short surviving 
mMGMT tumors in the IPA analysis (figure 6E). Further evidence comes from the 
CGGA cohort, where in mMGMT tumors signaling of TNF-α through NFκB was 
enriched in a patient cohort with worse prognosis31. Exceptional high TNF-NFκB 
scores were seen in 3/13 (23%) tumors of patients surviving < 6 months. 9/13 (62%) 
of tumors of the < 6 months group and 3/14 (21%) of tumors of the > 12 months 
group had scores > 0 for NFκB target genes (suppl. figure 9A-B). Additionally, the 
same pathway was enriched in the dataset of tumors from the TCGA collective with 
available microarray data (figure S8A).  
Signaling through interferon-α was the only pathway strongly activated in the group of 
tumors from patients with longer survival (figure 6D, table S6) translating into a 
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decreased function “infectious disease” (figure 6E), which has been confirmed by 
GSE and CGGA as response to interferon-α was the top enriched in patients with 
high MGMT gene expression and survival times of more than 12 months (figure 
S8B). STAT3 was both predicted to be upregulated in mMGMT and uMGMT tumors 
of patients with short survival compared to patients with longer survival times (figures 
6C and 6D).    
 
Discussion 
Most of the IDH mutant glioblastomas are MGMT promoter methylated32. In this 
study, genetic, epigenetic and transcriptional differe ces between MGMT methylated 
and unmethylated IDH wldtype glioblastomas have been explored.  
CNV and mutations do not differ between newly diagnosed mMGMT and uMGMT 
tumors. Survival data of patients from the TCGA cohort who received sole 
radiotherapy showed no diff rence in overall survival of mMGMT and uMGMT 
patients making it likely that minor changes in the molecular profile do not affect the 
clinical course of the disease in the absence of temozolomide.  
Methylation analysis with consensus clustering of more than 1000 glioblastoma 
samples revealed three different methylation clusters sharing similarities with 
published work21,22. The allocation into three clusters is relatively stable between 
different datasets. We found that mMGMT tumors were enriched in cluster 1 and 
uMGMT tumors in cluster 3. Cluster 1 shows higher average methylation values, 
explaining why almost all differentially methylated CpGs between mMGMT and 
uMGMT tumors are hypermethylated in mMGMT tumors. There are no distinct 
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methylation patterns of mMGMT and uMGMT, but MGMT promoter methylation is 
unevenly distributed within three main methylation clusters, with a higher chance of 
having a methylated MGMT promoter in the cluster with the highest average 
methylation. The survival advantage of MGMT promoter methylation was only 
present in the more favorable cluster 1, supporting that the prognostic impact of 
MGMT is dependent on the global methylation profile. Tumors of cluster 1 express 
higher levels of TERT, suggesting TERT promoter mutations being more frequently in 
that cluster where survival was strongly associated with MGMT promoter methylation. 
Patients with tumors of clusters 2 and 3 have low TERT expression and do not show 
a survival benefit with mMGMT, confirming mMGMT is only a survival advantage in 
high TERT expressing tumors29. Furthermore, TERT expression/promoter mutations 
might be associated with specific epigenetic subgroups with high methylation levels 
and the enriched high TNF-NFκB scores in cluster 3 may partly explain the 
chemoresistance in this cluster. However, these findings should be validated in 
further studies.  
A hypermutated genotype in some MGMT promoter methylated tumors upon 
progression had been published8. We specifically analyzed CNV and found PDGFRA 
predominantly amplified in MGMT promoter methylated progressive tumors. In paired 
samples, we found that uMGMT tumors loose PDGFRA amplifications upon 
progression, whereas mMGMT tumors tend to gain amplifications of PDGFRA. This 
might also be a resistance mechanism to therapy, especially in mMGMT tumors that 
are more vulnerable against chemotherapy with temozolomide.  
The frequency of CDK4 and MDM2 amplifications tended to be higher in progressive 
MGMT promoter unmethylated tumors, and in such cases preexisting CDKN2A 
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losses may change upon progression to a balanced state, which is consistent with 
the finding that CDKN2A loss and CDK4 amplification rarely occur in parallel 
regardless of MGMT promoter methylation status33. These specific changes cannot 
be explained by the function of the MGMT protein and are likely to be a response of 
the tumor to different efficacy of the alkylating chemotherapy. However, the CNV 
differences of PDGFRA, CDK4 and MDM2 are based on a limited tumor dataset and 
should therefore be viewed as preliminary. Robust statistical validation from larger 
number of samples will be required.  
In our comparison of patient groups with shorter versus longer survival we found 
differences in specific CNV as well as mutation frequencies and different gene 
expressions according to MGMT promoter methylation. However, a potential bias 
could be due to the lower number of patients receiving alkylating chemotherapy in 
both the methylated and unmethylated groups of patients who survived for less than 
6 months compared to the respective groups of patients living longer than 12 months.  
The predicted activation of the TNF-NFκB pathway in the group of short surviving 
mMGMT patients is supported by previous preclinical data showing upregulation of 
MGMT through high NFκB signaling and therefore increased chemoresistance 
34although this may not be uniformly dependent on the level of promoter inactivity, 
possibly contributing to the short survival times in patient with otherwise favorable 
MGMT promoter methylated tumors. Of note, it is more likely that glioblastomas of 
patients with longer survival show a downregulation of TNF-NFκB signaling, as we 
also found a higher NFκB signaling in unmethylated tumors not selected for survival 
compared to all methylated tumors and no difference when comparing tumors from 
Downloaded from https://academic.oup.com/neuro-oncology/article-abstract/doi/10.1093/neuonc/nox160/4093221/Molecular-differences-in-IDH-wildtype-glioblastoma
by guest
on 10 September 2017
Ac
ce
pte
d M
an
us
cri
pt
 
20 
 
patients with short survival and MGMT promoter methylated tumors against all 
patients with unmethylated glioblastomas.  
Likewise, interferon signaling through interferon α/β can sensitize MGMT promoter 
unmethylated glioblastomas to temozolomide35,36. There is an upregulation of the 
interferon-α pathway in uMGMT tumors and long survival compared to both patients 
with unmethylated tumors and short survival as well as patients with methylated 
tumors and long survival, suggesting that patients who survive relatively longer with 
the unfavorable uMGMT might have this survival benefit from increased interferon-α 
signaling and therefore increased chemotherapy sensitivity. This is of particular 
importance because most of the patients in the group of patients with longer survival 
despite having tumors with uMGMT received temozolomide. The data is supported 
by a dataset of the CGGA, although caution is required because of the low sample 
size. The predicted upregulation observed in our study supports the recently 
proposed therapeutic inhibition of STAT3 in glioblastoma patients37, at least for 
patients with glioblastomas lacking MGMT promoter methylation. 
In conclusion, MGMT promoter methylation status serves as a biomarker for 
temozolomide therapy and does not determine an otherwise molecularly distinct 
glioblastoma subpopulation in the newly diagnosed setting. The chance to find a 
molecular target for trial inclusion is not per se worse in the MGMT unmethylated 
population. Further, there is a clear signal from this data to demand a new tissue 
analysis for every trial at recurrence. Lastly, the data provide evidence for the 
TNF/NFκB pathway to be revisited in future trials. Temozolomide might be safely 
omitted in patients with MGMT promoter unmethylated glioblastomas in clinical trials, 
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especially when meaningful molecular markers predicting the response to 
experimental therapies are found by predictive molecular analyses.  
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Figure legends 
Figure 1: Copy number alterations in primary glioblastoma according to MGMT 
promoter methylation 
(A) Left panel: Overall survival of 143 glioblastoma patients with IDH1 wildtype 
tumors according to MGMT promoter methylation. Right panel: Survival analysis of 
patients with tumors of the TCGA dataset regardless of the treatment. (B) Left panel: 
Survival analysis of tumors of the TCGA glioblastoma database not treated with 
chemotherapy according to MGMT promoter methylation. Right panel: Survival 
analysis of the TCGA dataset treated with chemotherapy. (C) Graphical illustration of 
the percentage of CNV in the mMGMT and uMGMT group. (D) Relative fractions of 
DNA copy number alterations detected in the TCGA database according to MGMT 
promoter methylation. Shown are the means ± standard deviation. (E) Average 
fraction of mutations detected in the TCGA database according to MGMT promoter 
methylation. Shown are the means ± standard deviation.  
 
Figure 2: Differential methylation in primary glioblastoma according to MGMT 
promoter methylation 
From outside to inside of the circle: 1st circle: Hypermethylated genes in mMGMT 
tumors according to their chromosome position. Genes that were additionally 
downregulated in the RNAseq TCGA dataset are labeled in black, others in light red. 
2nd circle: All differentially methylated positions within a promoter region of a gene. 
3rd circle: Area of each DMR between mMGMT and uMGMT glioblastomas. 4th 
circle: All differentially methylated positions, including MGMT related on chromosome 
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10. Center: GBX2 mRNA expression in the TCGA dataset in mMGMT and uMGMT 
glioblastomas.  
 
Figure 3: IDH wildtype glioblastoma cluster into three different clusters 
 (A) Heatmaps of 2024 positions that are differentially methylated between mMGMT 
and uMGMT tumors in the dataset of primary tumors, excluding MGMT related and 
intergenomic positions. (B) Consensus clustering using k-means of all samples of the 
primary tumor dataset. Shown is the result for k = 3. (C) Plot showing the relative 
change in area under the CDF curve in the k-means unsupervised clustering of 
primary glioblastoma. (D) CDF plot with examples from k = 2 to k = 8. Three clusters 
were chosen as the optimal number. (E) Distribution of mMGMT and uMGMT primary 
tumors into the clusters 1, 2 and 3. (F) Comparison of the cluster assignments with 
the clusters from Cecarelli et al. 21 and Sturm et al. 22 for 65 glioblastoma samples of 
the TCGA database. (G) Mean methylation beta-values of the 2024 differentially 
methylated CpGs, (H) relative TERT expression and (I) TNF-NFκB score according 
to methylation clusters. The lower and the upper hinges correspond to the first and 
third quartiles. The upper and lower end of the whiskers correspond to the 1.5x IQR 
(inter quartile range) from the hinge.  
 
Figure 4: CNV changes in pairs of primary and progressive glioblastoma 
(A) CNV of the genes CDK4, CDKN2A, MDM2 and PDGFRA in a set of 49 paired 
glioblastoma samples at primary diagnosis and progression. MGMT promoter 
methylation is indicated in the first row. (B) Shift in gene dosages of CDK4, CDKN2A, 
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MDM2 and PDGFRA in paired samples of primary and progressive glioblastoma 
according to MGMT promoter methylation. (C) Examples of copy number profiles of 
three paired primary and progressive glioblastoma samples. Color code: PDGFRA = 
red, CDKN2A = yellow, CDK4 = blue, MDM2 = green.  
 
Figure 5: Molecular differences between uMGMT and mMGMT progressive 
glioblastomas  
(A) CNV of CDK4, MDM2, PDGFRA and CDKN2A in the cohort of the progressive 
tumors, grouped according to MGMT promoter methylation. (B) Comparison of 
CDK4, MDM2 and PDGFRA copy number variations between mMGMT and uMGMT 
tumors in the progressive situation. (C) Heat map of CNV of at set of 19 frequently 
altered genes in the progressive tumor collective. High frequencies of alterations are 
shown in red, low frequencies in blue. MGMT promoter methylation is indicated in the 
first row. (D) Copy number variation profiles in mMGMT and uMGMT tumors in the 
progressive situation.  
 
Figure 6: Comparison between glioblastomas of patients with different survival 
(< 6 months vs. > 12 months) according to MGMT promoter methylation status 
(A) Copy number variations of CDK4, EGFR and PDGFRA according to MGMT 
promoter methylation status and survival groups (< 6 months vs. > 12 months) of 
glioblastoma patients in the TCGA cohort. (B) Mutations of EGFR and TP53 
according to MGMT promoter methylation status and survival groups of TCGA 
glioblastoma patients. (C) GSE analysis (left) and IPA network analysis (right) 
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comparing results obtained for mMGMT tumors of patients with survival times < 6 
months vs. > 12 months. Prediction for upregulation is indicated in orange. (D) GSE 
analysis (left) and IPA network analysis (right) comparing results obtained for 
uMGMT tumors of patients with survival times < 6 months vs. > 12 months. 
Prediction for upregulation is indicated in orange, for downregulation in blue. (E) IPA 
of patients with survival times < 6 months vs. > 12 months. Enriched differentially 
regulated functions are visualized and the topics cellular movement, cell survival, 
signaling and proliferation as well as infectious disease are highlighted in red.  
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